Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium

被引：0
|
作者：
Van, Nooten F. [1 ]
Dewilde, S. [1 ]
Van Belle, S. [2 ]
Marbaix, S. [3 ]
机构：
[1] United BioSource Corp, Brussels, Belgium
[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[3] Pfizer, Brussels, Belgium
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A329 / A329
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Pazopalb Versus Sunitinib for Renal Cancer in the United States Response
    Delea, Thomas E.
    Amdahl, Jordan
    Diaz, Jose
    Nakhaipour, Hamid Reza
    El Khoury, Michelle Hackshaw
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (09): : 836 - 840
  • [42] COST-EFFECTIVENESS ANALYSIS OF USING EVEROLIMUS OR AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE FAILED TO USE OF PAZOPANIB OR SUNITINIB IN FIRST-LINE TREATMENT
    Romero Prada, M. E.
    Huerfano, L. M.
    Roa Cardenas, N. C.
    VALUE IN HEALTH, 2016, 19 (07) : A735 - A735
  • [43] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Nunez, S. M.
    Godoy, J., I
    Cardona, A. F.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Carranza, H.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [46] Does First-line Treatment Impact the Cost Effectiveness of Second-line Treatment for Elderly Metastatic Colon Cancer Patients?
    Mullins, C.
    Woldemichael, A.
    Zheng, Z.
    Onukwugha, E.
    Seal, B. S.
    Hanna, N.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S141 - S141
  • [47] COST-EFFECTIVENESS OF PAZOPANIB VERSUS SUNITINIB AND BEVACIZUMAB ASSOCIATED TO INTERFERON ALPHA AS FIRST LINE TREATMENTS FOR METASTATIC RENAL CELL CARCINOMA
    Pepe, C.
    Paladini, L.
    Sedlmayer, C.
    Machado, M.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [48] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System
    Meirelles, Isandra Oliveira
    Nunes Couto, Dulce Helena
    da Costa, Rodrigo Saar
    CADERNOS DE SAUDE PUBLICA, 2019, 35 (08):
  • [50] COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN
    Yamaguchi, M.
    Maeda, T.
    Morimoto, K.
    Chen, W.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
12345